GlaxoSmithKline Partners with Singapore for Formulation - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

GlaxoSmithKline Partners with Singapore for Formulation


GlaxoSmithKline (GSK) and the Institute of Chemical and Engineering Sciences (ICES) of Singapore’s Agency for Science, Technology and Research’s have signed a five-year strategic agreement to develop new evidence-based formulations (EBFs) specifically for emerging markets. .EBFs are often fixed-dose combinations of active drugs or new formulations with different pharmacokinetic properties, new routes of delivery, or improved safety profiles. ICES has a long standing relationship with GSK since 2003, and the development of EBFs will further strengthen the relationship between both parties. The collaboration leverages ICES’ strengths and expertise in synthesis, formulation and process development and GSK’s vast experience in drug-candidate selection, optimization, and product development in novel formulations. The collaboration will enhance ICES’ technical expertise and know-how in drug product formulation, analytical techniques, development and scale-up. It will develop a pool of local expertise in specialized formulation for pharmaceutical development in Singapore.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy

Click here